Addition of Sintilimab to Nanoparticle Albumin-Bound Paclitaxel and S-1 as Adjuvant Therapy in Stage IIIC Gastric Cancer

References

• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Sasako M , SakuramotoS, KataiHet al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol.29(33), 4387–4393 (2011).
   PubMed Web of Science ®Google Scholar
• Noh SH , ParkSR, YangH-Ket al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol.15(12), 1389–1396 (2014).
   PubMed Web of Science ®Google Scholar
• Yoshida K , KoderaY, KochiMet al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J. Clin. Oncol.37(15), 1296–1304 (2019).
   PubMedGoogle Scholar
• Chang JS , LimJS, NohSHet al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother. Oncol.104(3), 367–373 (2012).
   PubMed Web of Science ®Google Scholar
• Li P , HuangCM, ZhengCHet al. Comparison of gastric cancer survival after R0 resection in the US and China. J. Surg. Oncol.118(6), 975–982 (2018).
   PubMed Web of Science ®Google Scholar
• Kim SH , LeeHJ, ParkJHet al. Proposal of a new TNM classification for gastric cancer: focusing on pN3b and cytology-positive (CY1) disease. J. Gastric Cancer19(3), 329–343 (2019).
   PubMed Web of Science ®Google Scholar
• Kobayashi M , SakamotoJ, NamikawaTet al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J. Gastroenterol.12(9), 1412–1415 (2006).
   PubMed Web of Science ®Google Scholar
• Sakamoto J , MatsuiT, KoderaY. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer12(2), 69–78 (2009).
   PubMed Web of Science ®Google Scholar
• Sasaki Y , NishinaT, YasuiHet al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci.105(7), 812–817 (2014).
   PubMed Web of Science ®Google Scholar
• Shitara K , TakashimaA, FujitaniKet al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol. Hepatol.2(4), 277–287 (2017).
   PubMed Web of Science ®Google Scholar
• Takashima A , ShitaraK, FujitaniKet al. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Gastric Cancer22(1), 155–163 (2019).
   PubMed Web of Science ®Google Scholar
• Kinoshita J , FushidaS, TsukadaTet al. Comparative study of the antitumor activity of nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol. Rep.32(1), 89–96 (2014).
   PubMed Web of Science ®Google Scholar
• Shirasaka T , ShimamatoY, OhshimoHet al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs7(5), 548–557 (1996).
   PubMed Web of Science ®Google Scholar
• Kochi M , FujiiM, KanamoriNet al. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. Cancer Chemother. Pharmacol.60(5), 693–701 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang W , DuC, SunYet al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemother. Pharmacol.82(4), 655–660 (2018).
   PubMed Web of Science ®Google Scholar
• Shi Y , ZhangS, HanQet al. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget8(54), 92401–92410 (2017).
   PubMedGoogle Scholar
• Morimoto M , TobaH, AoyamaMet al. Phase 1 dose-escalation study of triweekly nab-paclitaxel combined with S-1 for HER2-negative metastatic breast cancer. Clin. Breast Cancer20(6), 448–453 (2020).
   PubMed Web of Science ®Google Scholar
• Nakayama N , IshidoK, ChinKet al. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Gastric Cancer20(2), 350–357 (2017).
   PubMed Web of Science ®Google Scholar
• Sakaguchi K , NakatsukasaK, TaguchiT. Phase I study of triweekly nab-paclitaxel combined with S-1 in patients with HER2-negative metastatic breast cancer. Anticancer Res.36(12), 6515–6519 (2016).
   PubMed Web of Science ®Google Scholar
• Tsurutani J , KuroiK, IwasaTet al. Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. Cancer Sci.106(6), 734–739 (2015).
   PubMed Web of Science ®Google Scholar
• He MM , WangF, JinYet al. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Sci.109(11), 3575–3582 (2018).
   PubMed Web of Science ®Google Scholar
• Robert C , LongGV, BradyBet al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med.372(4), 320–330 (2015).
   PubMed Web of Science ®Google Scholar
• Le DT , UramJN, WangHet al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med.372(26), 2509–2520 (2015).
   PubMed Web of Science ®Google Scholar
• Reck M , Rodriguez-AbreuD, RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• Fuchs CS , DoiT, JangRWet al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol.4(5), e180013 (2018).
   PubMed Web of Science ®Google Scholar
• Kang YK , BokuN, SatohTet al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet390(10111), 2461–2471 (2017).
   PubMed Web of Science ®Google Scholar
• Moehler M , ShitaraK, GarridoM. LBA6_PR nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann. Oncol.31(Suppl. 4), S1191 (2020).
   Google Scholar
• Boku N , RyuMH, OhDY. LBA7_PR nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann. Oncol.31(Suppl. 4), S1192 (2020).
   Google Scholar
• Wang J , FeiK, JingHet al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs11(8), 1443–1451 (2019).
   PubMed Web of Science ®Google Scholar
• Jiang H , ZhengY, QianJet al. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer20(1), 760 (2020).
   PubMed Web of Science ®Google Scholar
• Brierley JD , GospodarwiczMK, WittekindC, AminMB. TNM Classifcation of Maligant Tumours (8th Edition).Wiley Blackwell, NJ, USA (2016).
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. NIH National Cancer Institute, Division of Cancer Treatment & Diagnosis (2020). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40
   Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar